NCT03704077 2020-05-19An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction AdenocarcinomaBristol-Myers SquibbPhase 2 Withdrawn